Katey J Rayner from 30 Waterside Plz APT 28E, New York, NY 10010, age 49, Phone: (212)7060628

Mir-33 Inhibitors And Uses Thereof
view source
US Patent:

20120053227, Mar 1, 2012
Filed:

Aug 26, 2011
Appl. No.:

13/219347
Inventors:

Kathryn J. Moore - Westfield NJ, US
Yajaira Suárez - New York NY, US
Katey J. Rayner - New York NY, US
International Classification:

A61K 31/7115
A61P 9/10
A61P 3/00
US Classification:

514 44 A
Abstract:

The miRNA miR-33 is shown to inhibit the expression of carnitine O-octaniltransferase (CROT), Carnitine palmitoyltransferase 1A (CPT1a) and hydroxyacyl-CoA-dehydrogenase (HADHB), reduce fatty acid oxidation in hepatic cells, and target the insulin receptor substrate 2 (IRS-2) independent of its ability to elevating plasma high density lipoprotein (HDL) levels. MiR-33 inhibitors are also shown to increase cholesterol efflux from peripheral cells, such as cholesterol-laden macrophages present in atherosclerotic plaques. Compositions and methods are therefore provided for treating or preventing metabolic syndrome and atherosclerosis using miR-33 inhibitors. The miR-33 inhibitors are preferably antagomirs having a single-stranded nucleic acid sequence that is complementary to at least 12 contiguous nucleotides in miR-33 and therefore forms a duplex with miR-33 under physiological conditions.

Mir-33 Inhibitors And Uses Thereof
view source
US Patent:

20130150431, Jun 13, 2013
Filed:

Aug 26, 2011
Appl. No.:

13/817477
Inventors:

Carlos Fernandez-Hernando - New York NY, US
Kathryn J. Moore - Westfield NJ, US
Yajaira Suarez - New York NY, US
Katey J. Rayner - New York NY, US
Assignee:

NEW YORK UNIVERSITY - New York NY
International Classification:

C12N 15/113
US Classification:

514 44 A, 536 245
Abstract:

The miRNA miR-33 is shown to inhibit the expression of carnitine O-octaniltransferase (CROT), Carnitine palmitoyltransferase 1A (CPT1a) and hydroxyacyl-CoA-dehydrogenase (HADHB), reduce fatty acid oxidation in hepatic cells, and target the insulin receptor substrate 2 (IRS-2) independent of its ability to elevating plasma high density lipoprotein (HDL) levels. MiR-33 inhibitors are also shown to increase cholesterol efflux from peripheral cells, such as cholesterol-laden macrophages present in atherosclerotic plaques. Compositions and methods are therefore provided for treating or preventing metabolic syndrome and atherosclerosis using miR-33 inhibitors. The miR-33 inhibitors are preferably antagomirs having a single-stranded nucleic acid sequence that is complementary to at least 12 contiguous nucleotides in miR-33 and therefore forms a duplex with miR-33 under physiological conditions.

Use Of Heat-Shock Protein 27 For Cardiovascular Disease Prevention And Treatment
view source
US Patent:

8343916, Jan 1, 2013
Filed:

Nov 3, 2010
Appl. No.:

12/939065
Inventors:

Edward R. M. O'Brien - Ottawa, CA
Katey Rayner - New York NY, US
Yong-Xiang Chen - Ottawa, CA
Xiaoli Ma - Ottawa, CA
Assignee:

Ottawa Heart Institute Research Corporation
International Classification:

A61K 38/00
US Classification:

514 74
Abstract:

A method of reducing cholesterol in a subject is provided. The method may be used to decrease serum cholesterol and/or arterial wall cholesterol. The method comprises administering a therapeutically effective amount of heat shock protein 27 (HSP27), or a co-factor, variant or analogue thereof. The method may be used to treat, prevent or reverse cardiovascular disease (including atherosclerosis); to decrease atherosclerotic lesion formation or rupture; to decrease apoptosis within a plaque; to decrease macrophage accumulation; and/or to reverse the accumulation of atherosclerotic plaque mass in a subject. Kits and pharmaceutical compositions comprising HSP27 for preventing or treating of cardiovascular disease, such as atherosclerosis, are also provided.

Katey J Rayner